Lotte Chilsung Beverage (005300) Q4 2023 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2023 earnings summary
1 Nov, 2026Executive summary
FY23 consolidated sales rose 13.5% YoY to KRW 32,247 hundred million; operating profit fell 5.5% to KRW 2,107 hundred million, while net profit increased 27.0% to KRW 1,665 hundred million.
Q4 sales surged 37.3% YoY to KRW 9,184 hundred million, but operating profit declined 67.3% to KRW 80 hundred million.
Financial highlights
Q4 consolidated gross profit was KRW 3,040 hundred million, up 17.9% YoY; SG&A rose 26.7% to KRW 2,961 hundred million.
Q4 consolidated profit before tax increased to KRW 353 hundred million from KRW 27 hundred million; net profit rose to KRW 353 hundred million from KRW 58 hundred million.
FY23 consolidated operating margin was 6.5%, down 1.3 percentage points YoY; net margin was 5.2%, up 0.6 percentage points.
Outlook and guidance
FY24 consolidated sales guidance is KRW 42,000 hundred million and operating profit KRW 2,500 hundred million; targeted operating margin is 6.0%, down 0.5 percentage points from FY23.
Beverage guidance: sales KRW 20,200 hundred million (+3.4%), operating profit KRW 1,800 hundred million (+11.1%), and margin 8.9% (+0.6 percentage points).
Liquor guidance: sales KRW 8,500 hundred million (+5.7%), operating profit KRW 400 hundred million (+19.0%), and margin 4.7% (+0.5 percentage points).
2024 priorities include growth through health/lifestyle trends and global expansion, plus profitability actions in budgeting, promotion and pricing, supply chain, and cash flow.
Latest events from Lotte Chilsung Beverage
- Q3 profit contracted sharply, while FY2026 guidance projects growth and a Q4 return to profitability.005300
Q3 2026 - Sales and net profit rose year-over-year, with strong beverage and liquor performance.005300
Q2 2026 - Q1 2026 delivered sharp profit gains, margin expansion, and robust overseas segment growth.005300
Q1 2026 - Domestic sales and profits fell in Q4 2025, but overseas growth and 2026 recovery are forecast.005300
Q4 2025 - Profits and margins rose in Q3 2025, with overseas and health-focused products driving growth.005300
Q3 2025 - Profit growth in Q2 2025 driven by overseas and zero-calorie products, with strong full-year outlook.005300
Q2 2025 - Sales and profits fell, but zero-calorie and health products drove segment growth.005300
Q3 2024 - Q2 sales up 38.1% YoY, but net profit and margins fell as overseas drove growth.005300
Q2 2024 - Q1 2025 revenue and profit declined, with rising debt ratio and segment performance shifts.005300
Q1 2025